Site Search
Displaying results 311 - 320 of 345
Resource | Publications,
Unitaid produced a new strategy for 2013-2016. The strategy concentrates on 6 Strategic Objectives that focus on products needed to reduce the burden of the three diseases where that burden is highest, in the world’s poorest populations. To support implementation of the new strategy, Unitaid’s Board approved a new set of Key Performance Indicators (KPIs) that are aligned with the strategy and designed to measure results across the Strategic Objectives and over time. This report is the first to present results for the new KPIs and sets the benchmark against which subsequent years can be measured and achievements demonstrated.
Resource | Publications,
At the turn of the 21st century, the United Nations (UN) established 8 Millennium Development Goals (MDGs), with targets set for 2015. Designed to drive progress worldwide and endorsed by all countries, the targets have been the focus of international and national development efforts for more than a decade.
This special supplement of the Global Tuberculosis Report 2013 summarizes the status of progress towards targets set within the MDG framework and for the response to TB/HIV and multidrug-resistant TB (MDR-TB) specifically, and the actions needed to either move beyond or accelerate towards these targets. Snapshots are provided globally, regionally and for the 22 high-burden countries (HBCs) that have about 80% of the world’s TB cases and that have received the greatest attention at the global level since 2000.
Resource | Publications,
The purpose of UNITAID is to contribute to the achievement of global long-term goals for HIV, tuberculosis and malaria through its interventions in product markets. These goals have determined the Strategic Objectives described in this Strategy for the coming four years and are shared by the international community at large. The Strategic Objectives have also been guided by the market landscapes, which UNITAID regularly publishes and updates twice a year, and which identify opportunities for market interventions. The Objectives have been divided into three categories: active (UNITAID already supports interventions that will continue throughout the period of the Strategy), potential (clearly identified by the landscapes but not yet considered for funding) and exploratory (identified by experts and stakeholders but not yet vetted through landscape analysis).
Resource | Publications,
The technology landscape highlights current and emerging tools for improved diagnosis of TB. The emphasis of this report is on Nucleic acid amplification test (NAAT) products, where the most significant recent development has been seen. A variety of options, either commercially available or in late-stage development, are designed for detection of TB, first and/or second-line drug resistance, or for TB diagnosis and drug resistance combined. Commercialized technologies and those in late-stage development do hold promise in expanding the potential for TB diagnosis via NAATs. However, GeneXpert remains the leading technology in this area and is the last product endorsed by WHO in 2010. While a growing portfolio of TB NAAT assays are commercialized or in late-stage development, none is expected to be endorsed by WHO in 2013, and few tests are anticipated to have the necessary evidence base for endorsement over the next two to three years.
Resource | Publications,
This document is a semi-annual update to the second edition report. The purpose of this document is to highlight developments that have occurred since July 2013 – namely, in the areas of policy development, implementation and scale-up of the Xpert® MTB/RIF assay and efforts to define the characteristics of next-generation molecular tests that could replace smear microscopy. An updated technology pipeline is included for reference; however, a detailed report on newer technologies, including technologies other than nucleic acid amplification tests (NAATs), will be published in 2014 (third edition).
Resource | Publications,
The 2013 Report on Tuberculosis Research Funding Trends: 2005–2012 presents eight years of funding data to characterize annual investments by the world’s leading donors to TB R&D. The report compares current spending in six areas of research with the corresponding R&D funding targets outlined in the Stop TB Partnership’s Global Plan to Stop TB 2011–2015 and shows how these levels of investment have changed over time since 2005, the baseline year. The analysis reveals that in all six research categories, actual spending falls far short of the investments required to develop and introduce new tools to fight TB.
This is also the first year since TAG began reporting that the global funding total has decreased compared with the previous year—falling by $30.4 million. The $627.4 million spent on TB R&D in 2012 represents just 31.4% of the recommended $2 billion annual investment.
Resource | Publications,
Tuberculosis (TB) is a curable disease, but among the 8.7 million new cases in 2011, there were 1.4 million deaths. Currently available medicines can cure most cases of TB in six months, and advances in technology—including novel and repurposed medicines and regimens—hold promise as new or improved tools to treat drug resistant forms of the disease. However, many patients do not have access to appropriate TB medicines. Lack of access can be traced, in large part, to markets that do not function well.
This report is part of a broad and ongoing effort by UNITAID to understand the landscape for TB medicines so as to complement other tools and initiatives. As data on TB medicines markets are incomplete, UNITAID intends this report to serve primarily as a platform for stimulating discussion. That is, this report should be considered a preliminary analysis to: 1) engage key stakeholders in discussion of critical market shortcomings related to TB medicines; and 2) to identify potential market-based approaches to remedy these and establish or restore functional market dynamics.
Resource | Publications,
With this new Strategy 2013-2016, UNITAID enters what could be called the third stage of its
development.
UNITAID's mission has remained constant over the years. It increases access to treatment for HIV/
AIDS, TB and malaria for people in developing countries by leveraging price reductions of quality drugs and diagnostics, which currently are unaffordable for most developing countries, and to accelerate the pace at which they are made available.
The UNITAID Strategy 2013-2016 provides an excellent vision that will guide new investments. It
identifies the tools needed to implement the Strategy, of which many are already under development,
tried and tested. UNITAID remains creative in its approach, and is ready and able to develop new tools or engage in new partnerships that will ensure its objectives are met. UNITAID’s innovative source of income will continue to be well invested, and UNITAID will strive to increase its funding capacity through new and existing donors.
Resource | Publications,
The Global Fund has approved over $22.9 billion in grants for HIV, TB and malaria programmes since 2002. Nearly 40% of the money has gone towards procurement, making the Global Fund a major player in the market for commodities. With such leverage, the Fund is always looking to influence prices.
Resource | Publications,
The SAARC Regional Strategy for TB and HIV Co-infection recognizes that TB and HIV/AIDS are two major public health problems in the SAARC Region. Out of the eight countries, four countries- namely Afghanistan, Bangladesh, India and Pakistan are among 22 high TB burden countries, globally. TB is the most common opportunistic infection and the cause of death for those infected with HIV/AIDS. TB adds to the burden of illness of people infected with HIV while HIV accelerates the progress of TB infection to active TB disease, and has implications for the public health.
In this region, the HIV/AIDS prevalence in general population is still low but its prevalence
among high risk groups has increased during the last decade which is a cause of concern.
The role of ACSM is crucial in achieving a world free of TB and HIV/AIDS. The aim of Advocacy, Communication and Social Mobilization (ACSM) is to support National TB and HIV/AIDS Control Programmes of the SAARC Region to combat stigma and discrimination, improve case detection and treatment adherence, empower people affected by TB and HIV/AIDS and to mobilize political commitment and resources for TB and HIV/AIDS. ACSM strategy incorporates various types of communication programming, including mass media, interpersonal communication, community mobilization and advocacy.